AUS
NZ
UK
CA
USA
IND
Nyrada Inc (ASX:NYR), a clinical-stage biopharmaceutical firm, announced that 4,897,500 unquoted broker options expired unexercised on 29 June 2026, lowering the company's total NYRAI option pool and decreasing overall dilution. These options, issued on 29 June 2021 with a five-year term, had exercise prices of 40 cents, 60 cents, and 90 cents per share, all exceeding market prices at expiration. Confirmed in a company update lodged on 30 June 2026, no consideration was received by holders for the expired options. Investors monitoring Nyrada's capital structure will note the remaining unquoted option pool totals about 47.3 million securities across various tranches, while quoted Chess Depositary Interests (CDIs) outstanding amount to 245,490,330.
Key Points
- Company: Nyrada Inc (ASX:NYR)
- 4,897,500 unquoted broker options (NYRAI class) expired unexercised on 29 June 2026
- Options issued on 29 June 2021 with exercise prices of 40c (897,500 options), 60c (2,000,000 options), and 90c (2,000,000 options)
- No payment was made by Nyrada or received by holders upon expiry
- Post-lapse, remaining NYRAI options total 18,902,500 following concurrent new issuances
- Total quoted CDIs outstanding: 245,490,330; total unquoted options across all classes: approximately 47.3 million
- Investors should monitor future option issuances and capital structure updates as Nyrada advances its clinical pipeline
All Three Broker Option Tranches at 40c, 60c, and 90c Expire Simultaneously
The company update confirms that three separate tranches of unquoted broker options under the NYRAI code expired on 29 June 2026 without exercise. The first tranche included 897,500 options exercisable at 40 cents per share; the second, 2,000,000 options at 60 cents; and the third, 2,000,000 options at 90 cents. In total, these amounted to 4,897,500 options.
All tranches were issued on 29 June 2021, granting a five-year lifespan typical for broker or lead manager options linked to capital raises. Their concurrent expiry reflects this shared issuance date. Nyrada confirmed no consideration was paid upon expiry, consistent with out-of-the-money options lapsing.
Reasons Behind the Non-Exercise of 40c, 60c, and 90c Strike Price Options
The lapse of all three tranches without exercise indicates Nyrada's CDI price did not reach the lowest strike price of 40 cents during the five-year term, or holders chose not to exercise if it did. The company did not disclose current or historical share prices in the update, nor was an immediate share price impact evident publicly. The tiered strike prices suggest these options were incentives linked to progressively higher price targets.
Such broker options are typically granted to underwriters or lead managers as compensation for equity raising services. When the underlying security trades below the exercise price at expiry, holders lack financial incentive to exercise, and options expire worthless. This outcome slightly benefits existing shareholders by preventing dilution from up to 4,897,500 potential new CDIs.
Nyrada's NYRAI Option Pool Following Expiry and Concurrent Issuances
The update reconciles the NYRAI option class post-expiry. The total is now 17,300,000, calculated as 18,902,500 minus 200,000 (from a prior Appendix 2A) and minus 1,402,500 (from an Appendix 2A lodged on 29 June 2026). Concurrently, 200,000 and 1,402,500 new securities were issued and added to the quoted CDI total as referenced in those Appendix 2A forms.
The net NYRAI figure of 18,902,500 shown in the Part 3 Issued Capital table reflects these transactions but may not fully incorporate processing adjustments. The company notes that Part 3 figures are auto-generated and might not represent the most current issued capital if multiple forms are processed simultaneously. Investors should cross-check all Appendix 2A and 3H filings from 29–30 June 2026 for precise figures.
Detailed Breakdown of Nyrada's Unquoted Option Register Post-Expiry
Beyond the NYRAI class, Nyrada's option register includes ten other named series: 2,300,000 NYRAK options expiring 31 December 2027 at $0.20; 1,781,250 NYRAP options expiring 11 June 2032 at $0.19; 1,640,625 NYRAO options expiring 11 June 2031 at $0.19; 2,137,500 NYRAQ options expiring 30 June 2033 at $0.19; 3,000,000 NYRAS options expiring 12 November 2029 at $0.7968; 3,000,000 NYRAT options expiring 12 November 2030 at $0.7968; and 3,000,000 NYRAU options expiring 12 November 2031 at $0.7968.
The register also lists two nil-exercise-price option tranches: 600,000 NYRAV options expiring 12 November 2030 and 600,000 NYRAW options expiring 12 November 2031, convertible to CDIs at no cost if conditions are met. Additionally, 3,333,332 NYRAJ options expiring 30 June 2027 at $0.135 and 6,944,000 NYRAR options expiring 22 August 2027 at $0.45 remain outstanding. This broad register, with exercise prices from nil to $0.7968 and expiries spanning 2027 to 2033, reflects Nyrada's historical capital raises and remuneration arrangements as a listed entity.
Effect on Nyrada's Total Issued Capital and CDI Count
Following the expiry and related transactions, Nyrada's quoted CDI count stands at 245,490,330 per the Part 3 issued capital table. This figure includes additions of 200,000 and 1,402,500 CDIs from concurrent Appendix 2A filings. The total quoted CDI count may have slightly increased from the prior position due to these new issuances.
The expiry of 4,897,500 broker options permanently removes the maximum potential dilution from these instruments. Had all options been exercised at their respective strike prices, Nyrada would have received approximately $1.96 million from the 40c tranche alone, plus additional proceeds from the 60c and 90c tranches. Since no exercise occurred, no capital was raised and no new CDIs issued from these options. The company did not provide a formal proceeds calculation, as the options simply expired.
Insights from the Five-Year Life and Expiry of the 2021 Broker Options
Issued amid apparent optimism about Nyrada's near-term prospects, the 2021 broker options featured strike prices of 40c, 60c, and 90c, indicating anticipated share price appreciation. Their five-year term is generous, offering holders ample time to benefit from potential gains. The fact that none were exercised during this period offers insight into the company's share price trajectory, though investors should consult public trading data for detailed analysis.
As a clinical-stage biopharmaceutical company, Nyrada operates in a sector marked by long development timelines, binary clinical trial outcomes, and substantial funding needs before commercialisation. Share prices in this sector are often volatile and may remain subdued during clinical progress. The option expiries reflect these challenging conditions rather than company failure.
Concurrent Issuance of New CDIs and Options Alongside Option Expiry
The update references two Appendix 2A forms—one lodged prior and one on 29 June 2026—that recorded issuances of 200,000 and 1,402,500 new CDIs respectively. These issuances, increasing the quoted CDI pool, appear unrelated to the option expiries. The company did not disclose details such as purpose, price, or recipients in this update; investors should consult the respective Appendix 2A filings for more information.
The filing reconciliation indicates the total quoted CDI figure of 245,490,330 includes these additions, while the NYRAI option figure of 17,300,000 accounts for the 4,897,500 expired options and adjustments linked to these Appendix 2A events. The simultaneous transactions add complexity to issued capital reporting, and the company notes that automatically generated Part 3 figures may not reflect the most current data when multiple forms process concurrently.
Implications of the Expiry of 4.9 Million Dilutive Options on Nyrada's Capital Structure
From a capital management perspective, the lapse of 4,897,500 options without exercise is modestly positive for existing CDI holders, as it eliminates potential dilution from these shares. Although 4.9 million CDIs represent a small fraction of the approximately 245.5 million quoted CDIs outstanding, any reduction in dilution is generally favorable, especially in capital-intensive biotech sectors where further capital raises are common.
Investors should watch upcoming expiry dates for remaining options, notably the NYRAK options (2,300,000 at $0.20 expiring 31 December 2027) and NYRAJ options (3,333,332 at $0.135 expiring 30 June 2027), which have lower exercise prices and may be in or near the money depending on Nyrada's CDI price. The NYRAR tranche of 6,944,000 options at $0.45 expiring 22 August 2027 is the largest near-term tranche by volume and will also be closely monitored for potential dilution over the next 12 to 14 months.
Compliance with Regulatory Disclosure Through Appendix 3H Filing
Nyrada fulfilled its ASX Listing Rules disclosure obligations by lodging an Appendix 3H form on 30 June 2026, one day after the 29 June 2026 option expiry. This filing details the security class, quantity, cessation reason, date, and consideration paid (none), ensuring transparency about changes in issued capital.
The Appendix 3H filing supports accurate market understanding of total securities on issue, which is particularly important given Nyrada's extensive option register now comprising eleven unquoted option classes. The company provided no additional commentary, outlook, or operational updates beyond the required capital structure information in this filing.
